| 產品編號 | bsm-51578M |
| 英文名稱 | Mouse Anti-BCL10 antibody |
| 中文名稱 | BCL10單克隆抗體 |
| 別 名 | Bcl-10; B cell CLL/lymphoma 10; B cell lymphoma/leukemia10; B-cell leukemia/lymphoma 10; Bcl 10; c E10; c-E10; C81403; CARD containing apoptotic signaling protein; CARD containing molecule enhancing NF kappa B; CARD containing molecule enhancing NF kB; CARD containing molecule enhancing NFkB; CARD containing proapoptotic protein; CARD like apoptotic protein; CARMEN; Caspase recruiting domain containing protein; cCARMEN; cE 10; cE10; CED 3/ICH 1 prodomain homologous E10 like regulator; CED3/ICH1 prodomain homologous E10 like regulator; Cellular E10; Cellular homolog of vCARMEN; CIPER; CLAP; hCLAP; Mammalian CARD containing adapter molecule E10; mE 10; mE10; R-RCD1; BCL10_HUMAN. |
| 研究領域 | 腫瘤 細胞生物 信號轉導 細胞凋亡 細胞周期蛋白 轉錄調節因子 |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號 | G56 |
| 交叉反應 | Human,Mouse |
| 產品應用 | WB=1:500-2000,IHC-P=1:400-800,IHC-F=1:400-800,Flow-Cyt=1:100,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 26kDa |
| 細胞定位 | 細胞漿 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BCL10: 1-130/233 |
| 亞 型 | IgG1,Κ |
| 純化方法 | affinity purified by Protein G |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. [provided by RefSeq, Jul 2008] Function: Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1. Subunit: Contains 1 CARD domain. Subcellular Location: Cytoplasm > perinuclear region. Membrane raft. Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts. Tissue Specificity: Ubiquitous. Post-translational modifications: Phosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2. Phosphorylated by IKBKB/IKKB. DISEASE: Note=A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma). Translocation t(1;14)(p22;q32). Although the BCL10/IgH translocation leaves the coding region of BCL10 intact, frequent BCL10 mutations could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions. <>brNote=Defects in BCL10 are involved in various types of cancer. Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. Note=The gene represented in this entry may be involved in disease pathogenesis. Similarity: Contains 1 CARD domain. SWISS: O95999 Gene ID: 8915 Database links: Entrez Gene: 8915 Human SwissProt: O95999 Human |
| 產品圖片 |
Sample:
Lane 1: Daudi cell lysates
Primary: Anti-BCL10 (bsm-51578M) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution
Predicted band size: 26 kD
Observed band size: 30 kD
Paraformaldehyde-fixed, paraffin embedded (Mouse kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (BCL10) Monoclonal Antibody, Unconjugated (bsm-51578M) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Human kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (BCL10) Monoclonal Antibody, Unconjugated (bsm-51578M) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Blank control:Hela.
Primary Antibody (green line): Mouse Anti-BCL10 antibody (bsm-51578M)
Dilution: 1:100;
Secondary Antibody : Goat anti-mouse IgG-FITC
Dilution: 0.5ug/Test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20℃.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
Blank control: Hela.
Primary Antibody (green line): Mouse Anti-BCL10 antibody (bsm-51578M)
Dilution: 1:50;
Isotype Control Antibody (blue line): Mouse IgG
Secondary Antibody : Goat anti-mouse IgG-AF488
Dilution:
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at-20℃.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
